These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Mégnin-Chanet F; Bollet MA; Hall J Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763 [TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701 [TBL] [Abstract][Full Text] [Related]
5. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025 [TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase inhibition: past, present and future. Curtin NJ; Szabo C Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152 [TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Peralta-Leal A; Rodríguez MI; Oliver FJ Clin Transl Oncol; 2008 Jun; 10(6):318-23. PubMed ID: 18558578 [TBL] [Abstract][Full Text] [Related]
9. Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences. Mangerich A; Debiak M; Birtel M; Ponath V; Balszuweit F; Lex K; Martello R; Burckhardt-Boer W; Strobelt R; Siegert M; Thiermann H; Steinritz D; Schmidt A; Bürkle A Toxicol Lett; 2016 Feb; 244():56-71. PubMed ID: 26383629 [TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. He JX; Yang CH; Miao ZH Acta Pharmacol Sin; 2010 Sep; 31(9):1172-80. PubMed ID: 20676117 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of poly(ADP-ribose) polymerase in cancer. Plummer ER Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340 [TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase activity and inhibition in cancer. Dulaney C; Marcrom S; Stanley J; Yang ES Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320 [TBL] [Abstract][Full Text] [Related]
13. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Griffin RJ; Curtin NJ; Newell DR; Golding BT; Durkacz BW; Calvert AH Biochimie; 1995; 77(6):408-22. PubMed ID: 7578423 [TBL] [Abstract][Full Text] [Related]
14. Development of PARP inhibitors in oncology. Rodon J; Iniesta MD; Papadopoulos K Expert Opin Investig Drugs; 2009 Jan; 18(1):31-43. PubMed ID: 19053880 [TBL] [Abstract][Full Text] [Related]
17. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers. Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942 [No Abstract] [Full Text] [Related]
18. Targeting poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment. Sakamoto-Hojo ET; Balajee AS Anticancer Agents Med Chem; 2008 May; 8(4):402-16. PubMed ID: 18473725 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Curtin NJ; Szabo C Mol Aspects Med; 2013 Dec; 34(6):1217-56. PubMed ID: 23370117 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Lupo B; Trusolino L Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]